|Articles|January 1, 2003

January 2003
Volume 9
Issue 1

Medicaid Managed Care: Are Academic Medical Centers Penalized by Attracting Patients With High-Cost Conditions?

Author(s)Michele Heisler, MD, MPA, Sonya M. DeMonner, MPH, John E. Billi, MD

Download PDF: Medicaid Managed Care: Are Academic Medical Centers Penalized by Attracting Patients With High-Cost Conditions?

Articles in this issue

over 23 years ago

Article

Effects of Ambulatory-Care Pharmacist Consultation on Mortality and Hospitalization

over 23 years ago

Article

Identifying Individuals at Risk for the Development of Type 2 Diabetes Mellitus

over 23 years ago

Article

Impact of an Antidepressant Management Program on Medication Adherence

over 23 years ago

Article

Efficacy of Inhaled Corticosteroids Administered Once Daily for Asthma

over 23 years ago

Article

The Cost Effectiveness of 5 Interventions to Increase Mammography Adherence in a Managed Care Population

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Medicaid Managed Care: Are Academic Medical Centers Penalized by Attracting Patients With High-Cost Conditions?

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO

Childhood Influenza Vaccine Rates Decreased From 2017 to 2023

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year